Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Chromadex ( (CDXC) ).
On February 25, 2025, ChromaDex Corporation amended its Executive Employment Agreement with CEO Robert Fried, effective January 1, 2025, increasing his base salary to $650,000 and setting a target performance bonus at 75% of his salary. Additionally, the company granted Fried 1,518,600 performance stock units, which vest based on achieving specific stock price targets over a seven-year period, reflecting the company’s strategy to retain leadership and align executive incentives with shareholder value.
More about Chromadex
ChromaDex Corporation operates in the health and wellness industry, focusing on the development and commercialization of evidence-based dietary supplements and skin care products. The company is known for its flagship ingredient, nicotinamide riboside, marketed as Tru Niagen, which is aimed at improving cellular health and energy metabolism.
YTD Price Performance: 3.28%
Average Trading Volume: 452,647
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $432.3M
See more data about CDXC stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “You Want to Believe That You’re Not a Fool”: Tesla Stock (NASDAQ:TSLA) Slides as Customers Fight Back Against Self-Driving Promises
- AMD or Intel: Stifel Chooses the Better AI Chip Stock to Buy Ahead of Earnings
- “Move at a Glacial Pace”: Starbucks Stock (NASDAQ:SBUX) Slips With New Cross-Promotion Plan for The Devil Wears Prada 2